Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia

HIV Clin Trials. 2006 Sep-Oct;7(5):251-4. doi: 10.1310/hct0705-251.

Abstract

Method: Infectious complications were assessed in 25 HIV-HCV coinfected patients receiving 29 courses of HCV therapy (786 person-weeks).

Results: The infection rate (1.3 infections/100 person-weeks) was similar when compared to the rate in HIV-negative patients. HIV status and neutrophil nadir did not predict infection risk or rate.

Conclusion: Interferon dose reduction and/or G-CSF in HCVtreated HIV patients with neutropenia are not justified.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Bacterial Infections / epidemiology
  • Bacterial Infections / etiology*
  • Canada / epidemiology
  • Female
  • HIV Infections / complications*
  • HIV*
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy*
  • Hospitals, Urban
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Male
  • Mycoses / epidemiology
  • Mycoses / etiology*
  • Neutropenia / etiology
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins
  • Risk Factors
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2b
  • peginterferon alfa-2a